{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:46:33Z","timestamp":1787647593474,"version":"build-2736575974"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the efficacy and safety of further bevacizumab therapy in patients with platinum\u2010resistant ovarian cancer whose disease had progressed after bevacizumab plus chemotherapy. In this multicenter, open\u2010label, phase II trial (JGOG3023), patients were randomized 1:1 to a single\u2010agent chemotherapy alone (either pegylated liposomal doxorubicin [40 or 50\u00a0mg\/m<jats:sup>2<\/jats:sup> administered intravenously], topotecan [1.25\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously], paclitaxel [80\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously], or gemcitabine [1000\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously]) or single\u2010agent chemotherapy\u00a0+\u00a0bevacizumab (15\u00a0mg\/m<jats:sup>2<\/jats:sup> intravenously). The primary endpoint was investigator\u2010assessed progression\u2010free survival (PFS) according to RECIST version 1.1. Secondary endpoints were overall survival (OS), objective response rate (ORR), and response rate according to Gynecological Cancer Intergroup cancer antigen 125 criteria. In total, 103 patients were allocated to chemotherapy (n\u00a0=\u00a051) or chemotherapy\u00a0+\u00a0bevacizumab (n\u00a0=\u00a052). Median investigator\u2010assessed PFS was 3.1 and 4.0\u00a0mo in each group, respectively (hazard ratio [HR]\u00a0=\u00a00.54, 95% confidence interval [CI]: 0.32\u20100.90, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.0082). Median OS was 11.3 and 15.3\u00a0mo in each group, respectively (HR\u00a0=\u00a00.67, 95% CI: 0.38\u20101.17, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.1556). Respective ORRs were 13.7% and 25.0% (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.0599) and response rates were 16.7% and 21.4% (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.8273). The incidence of grade \u22653 treatment\u2010related AEs was 42.0% in the chemotherapy group and 54.9% in the chemotherapy\u00a0+\u00a0bevacizumab group; AEs were well tolerated, with only 2 and 12 events leading to discontinuation of therapy, respectively. Bevacizumab was effective beyond progressive disease and AEs were manageable. The observed improvement in PFS requires further verification.<\/jats:p>","DOI":"10.1111\/cas.15185","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T13:11:25Z","timestamp":1635599485000},"page":"240-250","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy and safety of standard of care with\/without bevacizumab for platinum\u2010resistant ovarian\/fallopian tube\/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-3333","authenticated-orcid":false,"given":"Tadahiro","family":"Shoji","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Iwate Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Niigata University School of Medicine Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Gynecology Shizuoka Cancer Center Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikou","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Iwate Medical University School of Medicine Iwate Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Tottori University School of Medicine Tottori Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Yamagata University Yamagata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Gynecology Aichi Cancer Center Hospital Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Kitasato Academic Research Organization Kitasato University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kamiura","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Osaka International Cancer Institute Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-5700","authenticated-orcid":false,"given":"Shinichi","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Faculty of Medicine Toho University Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Department of Gynecology Cancer Institute Hospital Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology St. Mary\u2019s Hospital Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1684"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70115-4"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt333"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014544121"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103799"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.0505"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30279-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4489"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70439-5"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3212"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30637-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4505-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"e_1_2_8_19_1","unstructured":"Japan Clinical Oncology Group.Common Toxicity Criteria for Adverse Events version 4.0 Japanese Translation (CTCAE\u2010JCOG).http:\/\/www.jcog.jp\/doctor\/tool\/ctcaev4.html. Accessed March 23 2000."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"e_1_2_8_21_1","first-page":"1057","article-title":"Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model","volume":"42","author":"Ishikura N","year":"2019","journal-title":"Oncol Rep"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1408"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0782"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1319-y"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.15185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T04:13:52Z","timestamp":1693109632000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/cas.15185"],"URL":"https:\/\/doi.org\/10.1111\/cas.15185","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"2021-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}